Targeting genetically modified macrophages to the glomerulus.
Macrophages are key players in the development of the majority of renal diseases and are therefore ideal cellular vectors for site specifically targeting gene therapy to inflamed glomeruli. Macrophages can be genetically modified using viral vectors ex vivo then re-introduced into the body where they can home to the diseased site. This review summarises current experience in efficiently targeting modified macrophages to the inflamed glomerulus focussing on the factors controlling macrophage localisation, macrophage gene transfer methods, in vivo gene delivery and results of recent investigations using modified macrophage gene therapy for glomerular disease.
Wilson
H M
HM
Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland. d.c.kluth@abdn.ac.uk
Kluth
D C
DC
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002465:Cell Movement / Q000235:genetics* / Q000502:physiology; D018014:Gene Transfer Techniques; D005818:Genetic Engineering / Q000379:methods; D005921:Glomerulonephritis / Q000473:pathology / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D007678:Kidney Glomerulus / Q000473:pathology*; D008262:Macrophage Activation / Q000235:genetics*; D008264:Macrophages / Q000502:physiology* / Q000637:transplantation* / Q000821:virology